Patient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma

David Cunningham(Royal Marsden NHS Foundation Trust), Dirk Arnold(Asklepios Klinik Altona), Ramón Salazar(Institut Català d'Oncologia), Emanuelly Varea Maria Wiegert(Hospital do Câncer III), Francesco Sclafani(Royal Marsden NHS Foundation Trust), Michel Ducreux(Université Paris-Saclay), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Alberto F. Sobrero(Ospedale Policlinico San Martino), Manuel Schmidt(Mologen (Germany)), Werner Scheithauer(Comprehensive Cancer Center Vienna), Christophe Tournigand(Université Paris-Est Créteil)
Annals of Oncology
December 1, 2017
10.1093/annonc/mdx711.074
Cited by 2

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k